LEUKEMOGENESIS

Essay

Submitted for partial fulfillment of Master Degree in Clinical and Chemical Pathology

By

Naglaa Mohamed Abd El-Aziz M.B.B.Ch.

Under Supervision of

Prof.Dr. Nehaiet Mahmoud Azmy

Professor of Clinical and Chemical Pathology Faculty of Medicine, Ain-Shams University

Ass.Prof.Dr. Tahani Ali El-Kerdany

Assistant Professor of Clinical and Chemical Pathology Faculty of Medicine, Ain-Shams University

Dr. Mona Ahmed Wahba

Lecturer of Clinical and Chemical Pathology Faculty of Medicine, Ain-Shams University

> Faculty Of Medicine Ain-Shams University 1997










My family My Parents My Husband and My Son



Naglaa

ACKNOWLEDGEMENT

I would like to express my deepest appreciation and my supreme gratitude to *Prof.Dr. Nehaiet Mahmoud Azmy*, Professor of Clinical and Chemical Patholgy, Ain-Shams University, for her kindness, offering me much of her valuable time, greatest support, valuable guidance, continuous supervision and great encouragement.

I would also like to express my great respect and gratitude to *Ass.Prof.Dr. Tahani Ali El-Kerdany*, Assistant Professor of Clinical and Chemical Patholgy, Ain-Shams University, for her remarkable help, supervision and unlimited generosity in time and effort.

I am deeply greatfull to *Dr. Mona Ahmed Wahba*, Lecturer of Clinical and Chemical Patholgy, Ain-Shams University, for her remarkable help, supervision and unlimited generosity in time and effort.

Many thanks to my Family, my mother, my father, my husband and my little son for their great support.



List of Contents

	Page
List of abbreviations	i
List of tables	iv
List of figures	ν
Introduction and Aim of the Work	1
Review of Literature	
I-New Concepts of Leukemogenesis:	3
Monoclonality as evidence for neoplasia.	4
Failure of the balance between differentiation and proliferation.	7
Cascade of interactions between proteins in development of myeloid precursors.	10
Colony-stimulating factors (CSFs) and myeloid leukemia	12
By passing genetic changes in suppression of leukemia.	15
Leukemia as a multi-step process.	17
II-Oncogenes and Leukemogenesis:	22
Function of protein products of oncogenes.	25
• Extracellular growth factors.	25
• Membrane associated tyrosine kinases (including growth factor receptors).	25
◆ Intracellular signal transducers.	26
◆ Nuclear oncogenes.	28
Tumor suppressor genes (recessive oncogenes, antioncogenes)	28
Activation of oncogenes in hematological malignancies	30
◆ Chromosomal translocation and rearrangement.	30
◆ Point mutation.	36
♦ Inactivation.	37
◆ Amplification.	38
Role of oncogenes in the different types of leukemia	39
◆ Oncogenes in ALL.	39
♦ Oncogenes in AML.	40

• Oncogenes in CLL.	42
• Oncogenes in CML.	43
III-Viruses and Leukemogenesis:	46
Virology and cell biology.	47
Molecular and biological features of HTLV-I.	48
Infection of cells and retrovirus replication.	<i>51</i>
Methods of transmission of retroviruses.	55
HTLV-I and leukemogenesis.	<i>57</i>
EBV and leukemogenesis.	60
• Viral replication and latency.	61
◆ EBV preceding Burkitt's lymphoma.	63
Erythroleukemia induction by the Friend SFFV.	67
• Effects of the SFFV on hematopoietic cells.	68
• Genetic elements of SFFV required for pathogenecity.	71
- Genetic structure of SFFV.	71
- Sequences in the SFFV responsible for pathogenecity and erythroid cell specificity.	72
 Mechanism of SFFV induced pathogenesis. 	<i>73</i>
 Malignant transforamtion of erythroid cells. 	75
IV-Chemical, Miscellaneous and Familial Diseases	<i>78</i>
Involved in Leukemogenesis:	
Chemical induced leuekmia	79
• Benzene.	<i>79</i>
• Tobacco smoke.	83
• Other possible chemical leukemogens.	88
Miscellaneous environmental factors.	89
Familial diseases.	91
V-Cancer Chemotherapy and Leukemia:	93
Historical background.	94
General characteristics of secondary AML and MDS.	95
Risk of secondary AML/MDS following individual primary	98
malignancies	
1-Hodgkin's disease.	98
2-Non-Hodgkin's lymphoma.	100

Cist of Contents

3-Testicular cancer.	102
4-Ovarian cancer.	105
5-Breast cancer.	106
6-Other primary malignancies.	107
VI-Irradiation and Leukemia	109
Survivors of atomic blasts.	110
Leukemia and exposure to electromagnetic fields.	113
Exposure to microwaves and risk of leukemia.	116
Radiotherapy and leuekmia risk	117
• Radiotherapy and cancer cervix leukemia risk.	118
• Radiotherapy and berast cancer leukemia risk.	120
• Leukemia and radiologist.	122
 Diagnostic radiography and risk of leukemia. 	122
Summary	125
Refrences	129
Arabic Summary	

List of Abbreviations

ABL Abelson murine leukemia virus.

ABV(D) Doxorubicin, Bleomycin, Vinblastine, and

Dacarbazine.

AEV Avian erythroblastosis virus.

ALAS Amino-levulinic acid synthetase.

ALL Acute lymphoblastic leukemia.

AML Acute myeloblastic leukemia.

AML M₃ Acute promyelocytic leukemia.

 $AML M_6$ Erythroleukemia.

ANLL Acute non-lymphoblastic leukemia.

ATL Adult T-cell leukemia.

Break-point cluster region.

BPV-1 Bovine Papilloma virus type-1.

BT 1,2,4 benztriol.

C-SIS Simian sarcoma virus.

CAT Catechol.

CFU Colony forming unit.

CFU-E Colony forming unit erythroid.CLL Chronic lymphoblastic leukemia.

CMF Cyclophosphamide, Methotrexate,

Fluoruracil.

CML Chronic myeloid leukemia. CSF Colony stimulating factor.

CT Chemotherapy.

CTCL Cutaneous T-cell lymphoma.DIF Differentiation inducing factor.DVB Cisplatin, Vinblastine, Bleomycin.

EBER Epstein-Barr encoded RNA.

Epstein-Barr virus.
Epo Erythropoietin.

Epo-R Erythropoietin receptor.

F-MulV Friend murine leukemia virus.F-SFFV Friend spleen focus forming virus.

FAB French-American-British.

FMS Feline sarcoma virus.

G-protein Growth protein.

 $G_{\ell}PD$ Glucose-6-phosphate dehydrogenase.

GDP Guanosine di-phosphate.

gp Glycoprotein.

Guanosine triphosphate.

H-RAS Heavy-murine sarcoma virus.

HD Hodgkin's disease.

HLA Human leukocyte antigen.

HPLC High performance liquid chromatography.

HQ Hydroquinone.

HTLV-I Human T-cell lymphotropic virus-I.

IL Interleukin.

IL-R Interleukin-receptor.

jak Janus kinase.

K-RAS Kristen-murine sarcoma virus.

Kb Kilobase.Kd Kilodalton.

LET Linear energy transfer.

Lmp-1 Latency membrane protein-1.

LTR Long terminal repeat.

M-CSF Macrophage-colony stimulating factor.

mdr Multi-drug resistance.

MDS Myelodysplastic syndrome.

MGI Macrophage and granulocyte inducers.